Skip to main content
TipRanks
Go Ultimate75% OFF

Integrum AB Class B (6Y1) AI Stock Analysis

0 Followers
DE:6Y1

Integrum AB Class B

(Frankfurt:6Y1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthMeaningful revenue expansion shows that Integrum’s products are gaining commercial traction and that demand is developing beyond a static installed base. Continued growth can improve operating leverage over time, provided the company contains costs and converts sales into sustainable margins.
Negative Factors
Severe Profitability DeteriorationNegative gross profit means current revenue is not covering the direct cost base, while deeply negative operating and net margins show losses extend through the business. This weakens internal funding capacity and makes a return to sustainable profitability dependent on significant cost and execution improvement.

Integrum AB Class B (6Y1) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%30%40%DE:6Y1-11.30%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 21.27M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-5.7
Beta (1Y)
0.68
Revenue Growth
4.66%
EPS Growth
1.71%
Country
Germany
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Integrum AB Class B Business Overview & Revenue Model

Company Description

Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-...

Integrum AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:6Y1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 75.39B26.649.13%1.72%-3.90%37.73%
SE:SECT.BSE:SECT.B64NeutralSEK 64.43B100.9830.26%0.70%13.94%5.70%
SE:SEZISE:SEZI55NeutralSEK 510.16M-5.23-35.44%―18.56%28.11%
SE:BACTI.BSE:BACTI.B53NeutralSEK 520.40M82.501.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:OSSDSE:OSSD45NeutralSEK 329.67M-6.59――-11.89%-11.85%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%DE:6Y1SE:GETI.BSE:SEZISE:BACTI.BSE:SECT.BSE:OSSDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:6Y1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:6Y1Integrum AB Class B0.68-0.09-11.99%
SE:GETI.BGetinge AB (UK)276.8071.2534.66%
SE:SEZISenzime AB3.25-1.81-35.87%
SE:BACTI.BBactiguard Holding AB14.85-1.50-9.17%
SE:SECT.BSectra AB Class B330.2047.0616.62%
SE:OSSDOssDsign AB2.98-7.42-71.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.